Jingsong Wang, MD, PhD
Chief Executive Officer
Dr. Jingsong Wang is the CEO of Harbour Biomed (HBM). Before founding HBM, he was the Head of China Research and Development and of Translational Medicine, Asia Pacific, for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets.
Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher’s laboratory at the Harvard School of Public Health.
Dr. Wang is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom.
Liang Schweizer, PhD
Chief Scientific Officer
Dr. Liang Schweizer is the CSO of Harbour BioMed (HBM). Before joining HBM, she headed the Sanofi Asia Cancer Research team, leading a group of scientists with the aim of identifying innovative solutions for Asian cancer patients, as well as supporting global oncology efforts through external partnerships. Before joining Sanofi, Dr. Schweizer was a Director at Bristol-Myers Squibb Company, leading a division of Lead Discovery and Optimization (LDO) and overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, her team made significant contributions to over 20 clinical candidates and 4 marketed drugs. Her expertise in antibody therapeutics and immuno-oncology is demonstrated by her co-authorship of several patents on immunotherapies. Before working at LDO, Dr. Schweizer was a senior research investigator in oncology drug discovery at BMS, leading several cancer drug discovery projects, as well as contributing to multiple exploratory and full-phase oncology programs. She also served as an Adjunct Assistant Professor at Hunter College, CUNY.
Dr. Schweizer graduated from the Biology Department of the University of Science and Technology of China (USTC), then went on to earn a Master's degree in Microbial Engineering from the University of Minnesota, with a minor in Chemical Engineering. Subsequently, Dr. Schweizer received her PhD from the Institute of Molecular Life Sciences at the University of Zurich under the guidance of Dr. Konrad Basler. Her postdoctoral training was in the laboratory of Nobel Laureate Dr. Harold Varmus at Memorial Sloan Kettering Cancer Center (MSKCC), where she specialized in Wnt signaling and cancer.
Chief Financial Officer
Mr. Jeff He is the CFO of Harbour BioMed (HBM). Before joining HBM, he was the Executive Vice President, Strategy & Operations, at the ShangPharma Group. Mr. He joined ShangPharma from TPG (Texas Pacific Group), where he served as Senior Vice President, managing two portfolio companies in the biopharmaceutical industry.
Before joining TPG, Mr. He managed business units for Danaher and Saint-Gobain in China, focusing on business expansion and profitability improvement.
Mr. He worked as a Strategy Consultant with Bain & Company after receiving his MBA degree from Goizueta Business School at Emory University. Prior to that, he was a Senior Financial Analyst at Intel.
George Liu, PhD
Head of Early Development
Dr. George Liu is the Head of Early Development at Harbour BioMed (HBM). Before joining HBM, he was Director of Clinical Pharmacology for Novartis Oncology, where he was responsible for all aspects of clinical pharmacology for oncology product development in China. Prior to joining Novartis, Dr. Liu worked at Sanofi, GSK, and Guilford Pharmaceuticals where he held positions with increasing responsibilities for both nonclinical and clinical pharmacokinetics and contributed to the discovery and/or development, including regulatory approval, of Lusedra®, Anoro®, Ellipta®, Insuman, Mozobil, Signifor ®, LEE011, LDK378, and LCI699.
Dr. Liu obtained his BS in Biology from Nanjing University in 1990 and PhD in Medicinal Chemistry and Molecular Pharmacology from the School of Pharmacy and Pharmaceutical Sciences of Purdue University in 1999.
Mai-Jing Liao, PhD
Head of Business Development
Dr. Mai-Jing Liao is the Head of Business Development at Harbour BioMed (HBM). Before joining HBM, Dr. Liao was at Xian Janssen Pharmaceutical Ltd. where he served in multiple roles with increasing responsibilities in Marketing, Strategic Marketing and was the Head of Business Development for Oncology and Biologics, and served as a liaison with J&J Innovation Center. He joined J&J’s Centocor US after receiving his MBA degree from Johnson Graduate School of Management at Cornell University.
Dr. Liao received his PhD degree in Biochemistry from University of North Carolina-Chapel Hill and was a postdoctoral fellow in Dr. Robert Weinberg’s laboratory at Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology (MIT).